| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
In the present study, HPV type-specific data from 260 women with FIGO Ib1-IVB cervical cancer suggested that HPV16 positivity may be an independent predictor of favorable survival in invasive cervical cancer. This finding is prepared for submission. Also, we have reported the following findings: 1) At least two colposcopy-directed biopsies should be taken for histological diagnosis. 2) Of women with LSIL cytology, those testing negative for at least eight of the highest-risk types of HPV (HPV16/18/31/33/35/45/52/58) may not need immediate colposcopy and biopsy. 3) HLA Clas II DRB1*1302 allele may have a protective effect against progression from CIN1 to CIN2/3 and 4) HPV testing was more sensitive than cytology in detecting posttreatment CIN 2+, and had an equal specificity compared with cytology.
|
